NCT01010880View on ClinicalTrials.gov

Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Multiple Myeloma
Interventions
DRUG

BKT140

BKT-140 drug substance is a highly selective CXCR4 antagonist. BKT140 will be injected S.C once at dose of 0.03, 0.1, 0.3, 0.9 mg/kg

Trial Locations (2)

31096

Department of Hematology and Bone Marrow Transplantation,Rambam Medical Center, Haifa

52621

Chaim Sheba Medical Center,Tel-Hashomer, Ramat Gan

Sponsors
All Listed Sponsors
lead

Biokine Therapeutics Ltd

INDUSTRY